Allergy Therapeutics plc

Transitioning its current interests in anti-allergy immunotherapy products into a broader R&D effort, UK-headquartered Allergy Therapeutics plc has extended its tie-up with two European biotechs, S

Two Swiss biotechs, Anergis SA and Virometix AG , are to join forces on the development of “ultra-fast” allergy immunotherapies, using Anergis’s expertise in allergy R&D and Virometix’s ability to

Allergy Therapeutics PLC is keen to ensure that lessons learnt from its failed Phase III birch pollen allergy trial are successfully applied to its Grass Phase III trial, which is still due to begin

Recent months have been marked by high-profile setbacks for a number of promising molecules being developed by companies in the Asia region, involving either the return of rights by licensees to origi